Exelixis Patent Company LLC

Exelixis, Inc.

Bristol-myers Squibb Compnay

X-ceptor Therapeutics, Inc.

William C Stevens, Jr

Raju Mohan

Richard Martin

Brett Bradley Busch

Michael Charles Nyman

Edwin J Schweiger

Shao Po Lu

Wei Xu

Yong Wang

Timothy Patrick Forsyth

Yinong Xie

Tie-Lin Wang

Brenton Todd Flatt

Xiao-Hui Gu

Alan Thomas Johnson

Christopher D Bayne

Venkataiah Bollu

Lynne Canne Bannen

Haixia Wang

Shao-Po Lu

Vasu Jammalamadaka

Ellen K Kick

Morrison B Mac

Grace Mann

Brant Clayton Boren

Lisa Esther Dalrymple

Jason H Wu

Haiying Zhang

Xiao Hui Gu

Tie Lin Wang

Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.

Imidazole based LXR modulators

Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Modulators of LXR

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

LXR modulators

Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R, R, R, Rand G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Compounds of the invention, such as compounds of formula (I): 

Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R, R, R, R, J, J, G, G, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

LXR and FXR modulators

Compounds of the following general structure for use in compositions and methods for modulating the activity of nuclear receptors are provided: The compounds are useable in compositions and methods for modulating the estrogen related receptors and are agonists, partial agonists, antagonists. or inverse agonists of ERR or ERR&#x3b1;.

Benzylthiazolone inhibitors of estrogen-related receptors (ERR)

Growing community of inventors

La Jolla, CA, United States of America

William C Stevens, Jr